TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02024945

Intervention type: DRUG
Intervention: Propiverine
Description: Propiverine 15 mg tablets or 30 mg regulated release capsules
Study: NCT00642967

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methoxy Polyethylene Glycol-epoetin Beta
Description: Methoxy polyethylene glycol-epoetin beta will be administered subcutaneously every 4 weeks for a total of 48 weeks in this single-arm study. The first dose of 120 or 200 mcg will be determined based on the previous dose of epoetin or darbepoetin received prior to administration of study treatment, while subsequent doses will be adjusted to maintain hemoglobin within the target range.
Study: NCT04493463

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylprednisolone 40 mg + Ropivacaine + Saline
Description: To infiltrate the study solution, the surgeon will inject the incision site with a 10 cm long, 22-gauge needle before the closing of the incision site. A standard volume of 10 ml in each level will be injected, based on the study by Milligan et al., with a total of 5ml study solution injected laterally into the erector spinae muscle and 5 ml subcutaneously along both margins of the incision. This standardization will be on the basis of the number of levels to be treated, and will be consistent in each patient. The depth of penetration will include the subcutaneous tissues, paravertebral muscles, along with the deep muscles surrounding the spinous process, lamina, transverse process and facet joints; the epidural space and intrathecal space will be spared. The local infiltration solution in the treatment group will consist of a total of 30 ml study solution, containing 1 ml of 40 mg methylprednisolone plus 15ml of 1% ropivacaine and 14 ml saline.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine + Saline
Description: To infiltrate the study solution, the surgeon will inject the incision site with a 10 cm long, 22-gauge needle before the closing of the incision site. A standard volume of 10 ml in each level will be injected, based on the study by Milligan et al., with a total of 5ml study solution injected laterally into the erector spinae muscle and 5 ml subcutaneously along both margins of the incision. This standardization will be on the basis of the number of levels to be treated, and will be consistent in each patient. The depth of penetration will include the subcutaneous tissues, paravertebral muscles, along with the deep muscles surrounding the spinous process, lamina, transverse process and facet joints; the epidural space and intrathecal space will be spared. The local infiltration solution in the control group will consist of a total of 30 ml study solution, containing 15 ml of 1% ropivacaine and 15ml saline.
Study: NCT02650895

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Efprezimod alfa
Description: Recombinant fusion protein consisting of the extracellular domain of mature human CD24 linked to the human immunoglobulin G1 (IgG1) Fc domain

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: 0.9% sodium chloride
Study: NCT04425460

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Favipiravir
Description: Favipiravir combined with supportive care recommended in the current National/Local guidelines. Favipiravir dosage and method of administration: Day 1 1800 mg x2; Day 2 up to a maximum of 14 days 600 mg x 3

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo combined with supportive care recommended in the current National/Local guidelines. Placebo dosage and method of administration: Day 1 1800 mg x2; Day 2 up to a maximum of 14 days 600 mg x 3
Study: NCT00810589

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levemir
Description: 0,4 IE per kg bodyweight

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Humalog NPL Insulin
Description: 0,4 IE per kg bodyweight
Study: NCT01502358

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tetravalent Dengue Vaccine (TVDV)
Description: Low dose delivered intramuscularly on Study Days 0, 30 and 90

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tetravalent Dengue Vaccine (TVDV) with Vaxfectin® (low-dose)
Description: Low dose: TVDV formulated with Vaxfectin®; 1.0 mL volume delivered intramuscularly on Study Days 0, 30 and 90

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tetravalent Dengue Vaccine TVDV with Vaxfectin® (High Dose)
Description: High dose: TVDV formulated with Vaxfectin®; 1.0 mL volume delivered intramuscularly on Study Days 0, 30 and 90
Study: NCT03765710

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Recommended protein intake
Description: Recommended protein intake in a mixed meal contained 13% protein, 54% carbohydrate, and 33% fat.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Elevated protein intake
Description: Increased protein intake in a mixed meal contained 26% protein, 44% carbohydrate, and 30% fat.
Study: NCT00136838

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Neutral or active cigarette cues
Description: Packets of cigarettes or cigarette smoke.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Neutral or active cigarette cues
Description: Packets of cigarettes or cigarette smoke.
Study: NCT00040742

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: ginger
Description: Given orally

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: ginger
Description: Given orally

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: ginger
Description: Given orally

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: placebo
Description: Given orally

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: placebo
Description: Given orally

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Given orally
Study: NCT03712176

Intervention type: BEHAVIORAL
Intervention: Lifestyle alteration
Description: Patients will receive self-report questionnaires to evaluate their quality of life, fatigue level, anxiety and depression, cognitive complaint, cognitive efficiency, nutritional quality and food preferences, and sedentary behavior. Patients will also do tests to determine their physical conditions : six-minute walk test (6MWT), 30-s chair-stand test. The intervention will be done at three stages of the patient's care pathway: 1 / before the adjuvant surgery (baseline), 2 / at 6 months after the surgery and chemotherapy 3 / at 7 months after radiotherapy treatment.

Intervention type: BEHAVIORAL
Intervention: Lifestyle alteration
Description: Patients will receive self-report questionnaires to evaluate their quality of life, fatigue level, anxiety and depression, cognitive complaint, cognitive efficiency, nutritional quality and food preferences, and sedentary behavior. Patients will also do tests to determine their physical conditions : six-minute walk test (6MWT), 30-s chair-stand test. The intervention will be done at three stages of the patient's care pathway: 1 / before the adjuvant surgery (baseline), 2 / at 6 months after the surgery and chemotherapy 3 / at 7 months after radiotherapy treatment.
Study: NCT02370823

Intervention type: PROCEDURE
Intervention: Regenexx SD
Description: stem cell treatment
Study: NCT02350335

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nicotine (transdermal)
Description: Application of transdermal nicotine replacement in smokers with acute aneurysmal hemorrhage
Study: NCT02531139

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MAP maintained at 80 mmHg
Description: Intervention group, MAP is maintained at 80 - 90 mmHg during anesthesia using continuous infusion of phenylephrine.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: MAP maintained at 60 mmHg
Description: Control group, MAP is maintained at minimum of 60 mmHg during anesthesia using continuous infusion of phenylephrine.
Study: NCT02011230

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hoist Group
Description: Hoist is a commercially available drink that is sold locally. This solution is isotonic meaning that it contains similar concentrations of salt and sugar that are found in the human body
Study: NCT00955643

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: oxygen

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: other
Study: NCT03748706

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PTI-125, 100 mg tablets
Description: PTI-125, 100 mg tablets taken twice a day for 28 days
Study: NCT01632852

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CSL362
Description: CSL362 is humanized monoclonal antibody that targets the alpha chain of the interleukin 3 receptor (IL3Rα; also known as CD123) and is optimised for enhanced activation of antibody-dependent cell-mediated cytotoxicity (ADCC) via natural killer cells.~CSL362 is a sterile solution for injection and will be administered by intravenous infusion to subjects in sequential, escalating dose level cohorts, at doses up to 12.0 mg/kg. CSL362 will be administered every 14 days for a total of 6 infusions per subject. The 6 infusions for each individual subject will contain the same dose of CSL362.
Study: NCT04340388

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dolutegravir 50 MG
Description: 15 participants will be randomized to remain on fully suppressive background antiretroviral therapy. The third agent will be switched to dolutegravir at the dose of 50 mg daily.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Antiretroviral/Anti HIV
Description: 15 participants with suppressed HIV disease for greater than or equal to 3 months will be randomized to remain on their current 2 or 3 drug fully suppressive antiretroviral regimen.
Study: NCT00930917

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Polyethylene cap
Description: In the cap group, the head of the infant was covered with a polyethylene cap immediately after birth

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Polyethylene wrap
Description: Infants in the wrap group were placed into the polyethylene bag, while still wet, up to their necks; only the head was dried.

Intervention type: OTHER
Group type: OTHER
Intervention: conventional treatment
Description: Infants in the control group were dried completely, according to International Guidelines for Neonatal Resuscitation.
Study: NCT03951766

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Smiling Instead of Smoking (SiS) App Version 2
Description: The investigators have developed a smartphone app that acts as a behavioral, in-the-pocket coach and uses positive psychology exercises to enhance quitting success. It is anonymous, portable, and provides just-in-time support, an important feature for smokers who smoke under specific conditions and circumstances. To support treatment, investigators use a positive psychology approach. The smartphone app administers positive psychology exercises to enhance and/or maintain positive affect, which is hypothesized to stimulate nondaily smokers to enact healthier alternatives to smoking by broadening their thought-action repertoire, increasing confidence, and decreasing craving and defensiveness about smoking-related health information.
Study: NCT02012036

Intervention type: DRUG
Intervention: Hexvix
Description: As this is a non-interventional study, detection of NMIBC with Hexvix is in a pre-defined group, chosen prior to and independently from the decision to enrol the subject in this study.~The detection with Hexvix should be in accordance with local Summary of Product Characteristics \[SmPC\].~Subjects will be treated in accordance with usual medical practice during their participation in this study, no additional assessment or tests will be required.
Study: NCT02596256

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib
Description: Apatinib (500 mg qd p.o.) until disease progression or intolerable toxicity

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: Docetaxel (60 mg/m2 qd d1 q3w i.v.) until disease progression or intolerable toxicity

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Docetaxel (60 mg/m2 qd d1 q3w i.v.) until disease progression or intolerable toxicity
Study: NCT04014751

Intervention type: OTHER
Intervention: Symptom Monitoring Intervention
Description: This study involves a cancer care delivery process improvement component where all cohort participants, at specified timepoints, are assessed for psychological distress, pain, fatigue, physical function, practical and supportive needs, and dietary and nutritional needs. Patients with severe elevations in psychological distress, physical symptoms or those who endorse supportive care and/or dietary needs are triaged in real time to appropriate providers within the health system (i.e., social work, nursing pool, nutrition services) to address elevated scores and/or stated needs. As such, within the context of this process improvement care delivery project, real time referrals function as interventional processes within the health system to route patients to relevant points of care based on their needs.
Study: NCT02564744

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Administered as IV Infusion.
Study: NCT01915095

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: rTMS
Description: small magnetic pulses will be given to the brain in a non invasive manner.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: rTMS
Description: small magnetic pulses will be given to the brain in a non invasive manner.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: rTMS
Description: small magnetic pulses will be given to the brain in a non invasive manner.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Sham rTMS
Description: sham or fake stimulation (TMS or rTMS) will be given to the brain in a non invasive manner
Study: NCT01915095

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Sham rTMS
Description: sham or fake stimulation (TMS or rTMS) will be given to the brain in a non invasive manner

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Sham rTMS
Description: sham or fake stimulation (TMS or rTMS) will be given to the brain in a non invasive manner
Study: NCT03898271

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Virtual World
Description: Participants will complete a synchronous PTSD training in an immersive virtual world environment.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Virtual World
Description: Participants will complete a synchronous PTSD training in an immersive virtual world environment.
Study: NCT00515528

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 4-peptide melanoma vaccine
Description: Experimental cancer vaccine given as a shot under the skin once every two weeks

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 4-peptide melanoma vaccine
Description: Experimental cancer vaccine given as a shot under the skin once every two weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ontak
Description: A single dose of Ontak given as an intravenous infusion over 30 minutes, 4 days before the first vaccine is given.
Study: NCT01506557

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: cholecalciferol
Description: dose 800 IU/day for 6 month
Study: NCT01915095

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Training
Description: at the direction of the researcher the participant will be instructed to do repetitive motor movements with their arm, hand or leg. this is called training
Study: NCT01506557

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: oil capsules
Study: NCT01345929

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CXA-201
Description: CXA-201 IV infusion (1500mg q8) for 7 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levofloxacin
Description: Levofloxacin IV infusion (750mg qd) for 7 days
Study: NCT02345655

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: urine drug testing
Description: Performed a OS-UDT test in general practice on patients starting buprenorphine

Intervention type: OTHER
Group type: OTHER
Intervention: no test
Description: normal procedure decided by the general practitioner
Study: NCT00334568

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosiglitazone XR (extended release) oral tablets
Description: Rosi XR tablets
Study: NCT01915095

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Motor Task
Description: participants will be asked to perform specific motor tasks or movements with their fingers, hands, arms or legs.
Study: NCT04666025

Intervention type: PROCEDURE
Intervention: Biospecimen Collection
Description: Undergo collection of nasopharyngeal swabs, blood, and saliva samples
Study: NCT00334568

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT03706768

Intervention type: OTHER
Group type: OTHER
Intervention: Glycocalyx
Description: Measure Degradation of the Glycocalyx
Study: NCT04666025

Intervention type: OTHER
Intervention: Diagnostic Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Intervention: Electronic Health Record Review
Description: Medical charts are reviewed

Intervention type: OTHER
Intervention: Questionnaire Administration
Description: Complete questionnaire
Study: NCT04651465

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tuning in to Kids
Description: A parenting program that includes 6 group supervisions of parents, where emotion coaching and promotion of kids emotional competence are main focus.
Study: NCT03211663

Intervention type: DEVICE
Intervention: MOTO Medial® UKA
Description: Knee replacement surgery with the MOTO Medial® UKA
Study: NCT01393795

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Qutenza
Description: 8% patch

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Tegaderm
Description: No active drug
Study: NCT01405703

Intervention type: OTHER
Intervention: xrays
Description: xrays from 2 week postop to 5 year postop

Intervention type: OTHER
Intervention: xrays
Description: xrays from 2 week postop to 5 year postop
Study: NCT01266226

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Autologous conditioned plasma
Description: 4mL autologous conditioned plasma application under the footprint following an arthroscopic repair of the rotator cuff.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Control group
Description: 4mL saline application under the footprint following an arthroscopic repair of the rotator cuff.
Study: NCT03125330

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Professional coaching
Description: Professional coaching is provided by the Principal Investigator via video conference.
Study: NCT01674946

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: saline
Description: intraduodenal perfusion

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: saline
Description: intraduodenal perfusion

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: saline
Description: intraduodenal perfusion
Study: NCT03125330

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Professional coaching
Description: Professional coaching is provided by the Principal Investigator via video conference.
Study: NCT04612829

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Medistus Antivirus Lozenges
Description: A blend of Kistosyn Extract with Gum Arabic
Study: NCT01674946

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: saline
Description: intraduodenal perfusion
Study: NCT04051749

Intervention type: PROCEDURE
Intervention: Noncardiac Vascular Surgery
Description: Noncardiac Vascular Surgery
Study: NCT03873727

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Prevenar13 (PCV13) and Pneumovax (PPS23)
Description: One dose of PCV13 at Month 0 and one dose of PPS23 at Month 12

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo / Pneumovax (PPS23)
Description: One dose of Placebo at Month 0 and one dose of PPS23 at Month 12

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Blood sample
Description: an additional 5 mL sample of blood at one of the visits, preferably at the first visit, concerning patients included in Parisian centers who did not participate in SPLENEVAC 1 study.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Blood sample
Description: an additional 5 mL sample of blood at one of the visits, preferably at the first visit, concerning patients included in Parisian centers who did not participate in SPLENEVAC 1 study.
Study: NCT03188263

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bright Light
Description: 1 hour daily morning light treatment provided through a head-worn device for 4 weeks with the following settings: irradiance is 230 μW/m2 and lux is 500 lux.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Dim Light
Description: 1 hour daily morning light treatment provided through a head-worn device for 4 weeks with the following settings: irradiance in this dimmed is reduced from 230 μW/m2 to 3 μW/m2, and lux reduced from 500 lux to 7 lux
Study: NCT00170326

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: dual-chamber pacemaker implantation
Description: Dual Chamber pacing via conventional DDD(R) right ventricular pacemaker or in case of ICD indication a standard dualchamber ICD device.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: biventricular dual-chamber pacemaker implant
Description: Biventricular pacemaker system or in case in ICD indication a BIV ICD
Study: NCT03748589

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: laryngeal mask airway
Description: i-gel laryngeal mask airway is a supraglottic airway device made from a medical grade thermoplastic elastomer , is a non-inflatable device to create anatomical seal of the pharyngeal, laryngeal and perilaryngeal structures and avoid compression trauma.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: laryngeal mask airway
Description: i-gel laryngeal mask airway is a supraglottic airway device made from a medical grade thermoplastic elastomer , is a non-inflatable device to create anatomical seal of the pharyngeal, laryngeal and perilaryngeal structures and avoid compression trauma.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: laryngeal mask airway
Description: i-gel laryngeal mask airway is a supraglottic airway device made from a medical grade thermoplastic elastomer , is a non-inflatable device to create anatomical seal of the pharyngeal, laryngeal and perilaryngeal structures and avoid compression trauma.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: laryngeal mask airway
Description: i-gel laryngeal mask airway is a supraglottic airway device made from a medical grade thermoplastic elastomer , is a non-inflatable device to create anatomical seal of the pharyngeal, laryngeal and perilaryngeal structures and avoid compression trauma.